Cite
HARVARD Citation
Augustin, M. et al. (2018). Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany. Journal of the European Academy of Dermatology and Venereology. pp. 2191-2199. [Online].